Open Access<p>The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer</p>
Author(s) -
Xia Chen,
Hong Jiang,
Fugui Ye,
Zhigang Zhuang
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s218524
Subject(s) - gemcitabine , microrna , cancer research , epigenetics , breast cancer , western blot , cell growth , transfection , cell culture , chemistry , microbiology and biotechnology , biology , cancer , medicine , gene , biochemistry , genetics
Gemcitabine is proven to be the first-line standard treatment of breast cancers. Yet, little is known involving gemcitabine resistance and remains largely to be elucidated.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom